Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis
Open Access
- 13 November 2013
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (2) , 505-511
Abstract
Clinical trials of the human rotavirus vaccine Rotarix™ (RV1) have demonstrated significant reductions in severe rotavirus gastroenteritis (RVGE) in children worldwide. However, no correlate of vaccine efficacy (VE) has yet been established. This paper presents 2 analyses which aimed to investigate whether serum anti-RV IgA measured by ELISA 1 or 2 mo post-vaccination can serve as a correlate of efficacy against RVGE: (1) In a large Phase III efficacy trial (Rota-037), the Prentice criteria for surrogate endpoints was applied to anti-RV IgA seropositivity 1 mo post-vaccination. These criteria determine whether a significant vaccine group effect can be predicted from the surrogate, namely seropositivity (anti-RV IgA concentration >20 U/mL); (2) Among other GSK-sponsored RV1 VE studies, 8 studies which assessed immunogenicity at 1 or 2 mo post-vaccination in all or a sub-cohort of enrolled subjects and had at least 10 RVGE episodes were included in a meta-analysis to measure the regression between clinical VE and VE predicted from immunogenicity (VE1). In Rota-037, anti-RV IgA seropositivity post-vaccination was associated with a lower incidence of any or severe RVGE, however, the proportion of vaccine group effect explained by seropositivity was only 43.6% and 32.7% respectively. This low proportion was due to the vaccine group effect observed in seronegative subjects. In the meta-analysis, the slope of the regression between clinical VE and VE1 was statistically significant. These two independent analyses support the hypothesis that post-vaccination anti-RV IgA seropositivity (antibody concentration ≥20 U/mL) may serve as a useful correlate of efficacy in clinical trials of RV1 vaccines.Keywords
This publication has 34 references indexed in Scilit:
- Protective Effect of Natural Rotavirus Infection in an Indian Birth CohortNew England Journal of Medicine, 2011
- Human Rotavirus Vaccine Is Highly Efficacious When Coadministered With Routine Expanded Program of Immunization Vaccines Including Oral Poliovirus Vaccine in Latin AmericaThe Pediatric Infectious Disease Journal, 2011
- Immunogenicity and safety of the human rotavirus vaccine Rotarix™ co-administered with routine infant vaccines following the vaccination schedules in EuropeVaccine, 2010
- Norovirus gastroenteritis in young children receiving human rotavirus vaccineScandinavian Journal of Infectious Diseases, 2010
- Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled studyVaccine, 2009
- Comment on: Confidence limits for the ratio of two rates based on likelihood scores: non-iterative methodStatistics in Medicine, 2004
- Rotavirus Disease in Finnish Children: Use of Numerical Scores for Clinical Severity of Diarrhoeal EpisodesScandinavian Journal of Infectious Diseases, 1990
- Comparison of seven kits for detection of rotavirus in fecal specimens with a sensitive, specific enzyme immunoassayDiagnostic Microbiology and Infectious Disease, 1987
- Protective effect of preexisting rotavirus‐specific immunoglobulin A against naturally acquired rotavirus infection in childrenJournal of Medical Virology, 1987
- Human Rotavirus Studies in Volunteers: Determination of Infectious Dose and Serological Response to InfectionThe Journal of Infectious Diseases, 1986